Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.33 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169411 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HRH4PIK3C2APIK3C2BPIK3CA | |
| SCHEMBL23576859 | 0.89 | FNTA (0.33) | HRH4FNTAFNTBMAT2A | |
| SCHEMBL29909295 | 0.89 | FNTA (0.33) | HRH4FNTAFNTBMAT2A | |
| SCHEMBL23601304 | 0.88 | PIK3C2A (0.32) | ALDH1A1PIK3C2APIK3C2BPIK3CAMTOR | |
| SCHEMBL29909937 | 0.88 | PIK3C2A (0.32) | ALDH1A1PIK3C2APIK3C2BPIK3CAMTOR | |
| SCHEMBL23601235 | 0.87 | FNTA (0.40) | ALDH1A1HRH4FNTAFNTBMAT2A | |
| SCHEMBL29909768 | 0.87 | FNTA (0.40) | ALDH1A1HRH4FNTAFNTBMAT2A | |
| SCHEMBL29909216 | 0.86 | FNTA (0.32) | HRH4FNTAFNTBMAP4K4 | |
| SCHEMBL23577231 | 0.86 | FNTA (0.32) | HRH4FNTAFNTBMAP4K4 | |
| SCHEMBL23578133 | 0.85 | FNTA (0.33) | FNTAFNTBMAT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ALDH1A1 4095/4885HRH4 3793/4885PIK3C2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.